New Aid for Conductive Hearing Loss
Medical device company Otorix AB aims to launch its latest project, the Adjoin concept, next year. It is a hearing aid for patients with conductive hearing losses.
Otorix AB is a medical device company, based in Gothenburg, which develops new solutions for hearing rehabilitation. The company's CEO Patrik Westerkull, MSc, has worked with bone conduction for many years. He has, for instance, been responsible for the hearing division of Nobel Biocare and founded therefrom Entific Medical where he was head of R&D until 2002. Entific was acquired by Cochlear in 2005.
In 2004, he founded Otorix and developed the Ponto™ system, now owned by Oticon A/S. He is also the inventor of the Adjoin concept, Otorix' latest project, for patients with a conductive hearing loss.
"Adjoin is an adhesive attachment for the sound processor Bonect. It's more comfortable and aesthetic than bone conductors retained with magnets or band arrangements, and ideal for children and also some adults," he says.
Bonect, which is currently under development, picks up sound and converts it into vibrations, which are sent through the skull bone, directly to the inner ear. This bypasses any hearing loss that the patient has in the ear canal or middle ear.
”Though implant devices are stronger for patients with combined hearing losses, non-implant devices are suitable for patients with pure conductive hearing losses and may also be used for hearing losses with an uncertain duration. It is also a good long-term solution for patients who are unsuitable or unwilling to undergo implant surgery,” Patrik Westerkull comments.
Sound Processor is Snapped on
Adjoin is attached on the skin, with no hair in-between, and changed about twice a week. It creates no pressure, which makes it very comfortable, and it is swim and shower compatible. The sound processor is snapped on to Adjoin and can be easily disconnected by pressing and tilting.
Clinical studies in the UK, at a big paediatric clinic in Birmingham, have shown promising results with no adverse side-effects.
"I've personally visited the clinics, and to meet the children experiencing the great benefits of Adjoin is the best reward you can get. The children's and their parents’ greatest concern was that the study would end. The clinics are also happy to be able to provide this solution,” tells Patrik Westerkull.
The Adjoin concept is currently in the final development phases and the company has discussions with commercial partners.
"We aim for market launch sometime next year," he concludes.